Cell cycle regulators in bladder cancer: Relationship to schistosomiasis

被引:20
作者
Eissa, S [1 ]
Ahmed, MI
Said, H
Zaghlool, A
El-Ahmady, O
机构
[1] Ain Shams Univ, Fac Med, Dept Biochem, Oncol Diagnost Unit, Cairo, Egypt
[2] Natl Canc Inst, Dept Surg Oncol, Cairo, Egypt
[3] Ain Shams Fac Pharm, Dept Biochem, Cairo, Egypt
关键词
bladder cancer; bilharziasis; p21; cyclin D; P15; P16; tumor suppressor genes;
D O I
10.1080/15216540400013903
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dysregulation of cell cycle control may lead to genomic instability, neoplastic transformation and tumor progression. In terms of the particular roles in regulation of the cell-cycle, p21(WAF1) causes growth arrest through inhibition of cyclin-dependant kinases required for G1/S transition. P16 (INK4A) and p15 (INK4B) are thought to act as tumor suppressors, since their inactivation and/or deletion are observable in various types of malignancies. Cyclin D1 is hypothesized to control cell cycle progression through the G1-S check point. The present study evaluated p21 expression, p16 and p15 gene deletion and cylin D1 expression in bladder carcinoma among Egyptian patients, in relation to different clinicopathological features of the tumors and presence or absence of bilharziasis. Tissue specimens were obtained from 132 patients with bladder carcinoma and 50 normal tissue samples from the same patients served as control. P21 was determined by Western blot (WB) and enzyme immunoassay (EIA), p16 and p15 gene deletions were examined by polymerase chain reaction (PCR) and Cyclin D1 was detected by WB. Levels of p21 were lower in malignant tumors than in normal tissues. Lower expression of p21 was evident in lymph node positive, well differentiated tumors and squamous cell carcinoma (SCC) than in lymph node negative, poorly differentiated tumors and transitional cell carcinoma (TCC). In all normal samples, p15 and p16 genes were detected while cyclin D1 was not detected. P16 and p15 genes were deleted in 38.7% (41/106) and 30.2% (32/106) of bladder tumors respectively. The deletion of both genes was associated with poor differentiation grade and presence of bilharziasis. P16 deletion was also correlated to advancing tumor stage. Cyclin D1 was expressed in 57.5% of bladder tumors (69/120), where its expression was correlated to early stage, well differentiation grade, schistomiasis, and low levels of p21. Cell cycle is dysregulated in bladder carcinoma. This was evident from the increased expression of cyclin D1, the decreased levels of p21 and the deletion of p15 and p16 genes. Moreover, p16 and p15 gene deletion was related to tumor progression and might have a role in bilharzial bladder carcinogenesis. Cyclin D1 over-expression appears to be an early event in bladder cancer and might explain bilharzial associated bladder carcinogenesis.
引用
收藏
页码:557 / 564
页数:8
相关论文
共 30 条
  • [1] TOO MANY RODENT CARCINOGENS - MITOGENESIS INCREASES MUTAGENESIS
    AMES, BN
    GOLD, LS
    [J]. SCIENCE, 1990, 249 (4972) : 970 - 971
  • [2] [Anonymous], PCR PRACTICAL APPROA
  • [3] [Anonymous], 1992, MANUAL STAGING CANC
  • [4] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [5] Genetic alterations of P16INK4A and P14ARF genes in human bladder cancer
    Chang, LL
    Yeh, WT
    Yang, SY
    Wu, WJ
    Huang, CH
    [J]. JOURNAL OF UROLOGY, 2003, 170 (02) : 595 - 600
  • [6] The regulation of E2F by pRB-family proteins
    Dyson, N
    [J]. GENES & DEVELOPMENT, 1998, 12 (15) : 2245 - 2262
  • [7] Expression of p21WAF1/CIP1 in bladder cancer:: Relation to schistosomiasis
    Eissa, S
    Swelam, M
    Shaker, Y
    Fattah, MA
    Khalifa, A
    [J]. IUBMB LIFE, 1999, 48 (01) : 115 - 119
  • [8] Eissa S, 1998, CLIN CHEM, V44, P1423
  • [9] Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC)
    Eissa, S
    Ali-Labib, R
    Khalifa, A
    [J]. CLINICA CHIMICA ACTA, 2000, 300 (1-2) : 159 - 169
  • [10] Bladder cancer in Africa: Update
    El Mawla, NG
    El Bolkainy, MN
    Khaled, HM
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (02) : 174 - 178